Skip to main content
Explore URMC

menu

Myelodysplastic Syndromes: A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Research Question:
How does the investigational drug pracinostat work and how safe is it when given with azacitidine?

Basic Study Information

Purpose:
In this research study, you will take either pracinostat or placebo 3 times a week for 3 weeks in a row followed by 1 week of rest. All subjects will receive azacitidine.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03151304?term=MEI-011&rank=1
Study Reference #: IMDS17095

Lead Researcher (Principal Investigator)

Lead Researcher: Jason Mendler

Study Contact Information

Study Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Email: Brandon_Delorme@URMC.Rochester.edu

Additional Study Details

Return to Search